Spots Global Cancer Trial Database for Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Official Title: Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
Study ID: NCT00204594
Conditions
Study Description
Brief Summary: Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis.
Detailed Description: Phase I/II clinical trial to analyze safety and efficiency of intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs in patients with metastatic melanoma stage III/IV and unresectable metastasis. The antibody is directed against epitops of human CD28 and the melanoma associated surface antigen HMV-MAA. Treatment over 5 days with dose escalation.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Tuebingen, Department of dermatology, Tuebingen, , Germany
Contact Details
Name: Garbe Claus, Prof. Dr.
Affiliation: Department of dermatology, university of tuebingen
Role: PRINCIPAL_INVESTIGATOR
Name: Gundram Jung, Prof. Dr.
Affiliation: University of Tuebingen, Dept. of Immunology
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
